Literature DB >> 29938774

Daratumumab proves safe and highly effective in AL amyloidosis.

Jack Khouri1, Andrew Kin2, Bicky Thapa3, Frederic J Reu1, Naresh Bumma2, Christy J Samaras1, Hien D Liu1, Mary A Karam1, Janice Reed1, Saveta Mathur1, Beth M Faiman1, Georgia Devries2, Jeffrey Zonder2, Jason Valent1.   

Abstract

Entities:  

Keywords:  AL amyloidosis; daratumumab; monoclonal antibodies; multiple myeloma

Mesh：

Substances：

Year:  2018        PMID： 29938774     DOI： 10.1111/bjh.15455

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  13 in total

Review 1.  Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details.

Authors:  Vaishali Sanchorawala
Journal:  Blood Adv       Date:  2019-01-22

Review 2.  New developments in diagnosis, risk assessment and management in systemic amyloidosis.

Authors:  Iuliana Vaxman; Angela Dispenzieri; Eli Muchtar; Morie Gertz
Journal:  Blood Rev       Date:  2019-11-02       Impact factor: 8.250

3.  Organ responses with daratumumab therapy in previously treated AL amyloidosis.

Authors:  Alfred Chung; Gregory P Kaufman; Surbhi Sidana; Erik Eckhert; Stanley L Schrier; Richard A Lafayette; Sally Arai; Ronald M Witteles; Michaela Liedtke
Journal:  Blood Adv       Date:  2020-02-11

Review 4.  Efficacy and safety of intravenous daratumumab-based treatments for AL amyloidosis: a systematic review and meta-analysis.

Authors:  Chunyan Sun; Xiaohong Wang; Renyi Zhang; Lingjie Xu; Bin Wang; Jian Li
Journal:  Cancer Cell Int       Date:  2022-07-04       Impact factor: 6.429

5.  Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.

Authors:  Giovanni Palladini; Efstathios Kastritis; Mathew S Maurer; Jeffrey Zonder; Monique C Minnema; Ashutosh D Wechalekar; Arnaud Jaccard; Hans C Lee; Naresh Bumma; Jonathan L Kaufman; Eva Medvedova; Tibor Kovacsovics; Michael Rosenzweig; Vaishali Sanchorawala; Xiang Qin; Sandra Y Vasey; Brendan M Weiss; Jessica Vermeulen; Giampaolo Merlini; Raymond L Comenzo
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

6.  Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study.

Authors:  Vaishali Sanchorawala; Shayna Sarosiek; Amanda Schulman; Meredith Mistark; Mary Ellen Migre; Ramon Cruz; J Mark Sloan; Dina Brauneis; Anthony C Shelton
Journal:  Blood       Date:  2020-04-30       Impact factor: 22.113

Review 7.  Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021.

Authors:  M Hasib Sidiqi; Morie A Gertz
Journal:  Blood Cancer J       Date:  2021-05-15       Impact factor: 11.037

Review 8.  Comprehensive Review of AL amyloidosis: some practical recommendations.

Authors:  Rama Al Hamed; Abdul Hamid Bazarbachi; Ali Bazarbachi; Florent Malard; Jean-Luc Harousseau; Mohamad Mohty
Journal:  Blood Cancer J       Date:  2021-05-18       Impact factor: 11.037

9.  Light chain lambda myeloma with fatal AL cardiac amyloidosis in a 21-year-old patient: A case report and review.

Authors:  Vincent Camus; Sydney Dubois; Pierre-Alain Thiébaut; Stéphane Lepretre; Pascal Lenain; Jean-Michel Picquenot; Elena-Liana Veresezan; Arnaud François; Dominique Penther; Fabrice Bauer; Arnaud Jaccard; Fabrice Jardin
Journal:  Clin Case Rep       Date:  2019-05-07

10.  Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome.

Authors:  Christian Nitsche; Stefan Aschauer; Andreas A Kammerlander; Matthias Schneider; Thomas Poschner; Franz Duca; Christina Binder; Matthias Koschutnik; Julian Stiftinger; Georg Goliasch; Jolanta Siller-Matula; Max-Paul Winter; Anahit Anvari-Pirsch; Martin Andreas; Alexander Geppert; Dietrich Beitzke; Christian Loewe; Marcus Hacker; Hermine Agis; Renate Kain; Irene Lang; Diana Bonderman; Christian Hengstenberg; Julia Mascherbauer
Journal:  Eur J Heart Fail       Date:  2020-02-20       Impact factor: 15.534
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.